Keyword Analysis & Research: hengrui
Keyword Research: People who searched hengrui also searched
Search Results related to hengrui on Search Engine
-
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
https://www.hrssd.com.cn/en/about.html
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs. We are a well-known supplier of oncology drugs, surgical drugs, and interventional imaging solutions in China.
DA: 83 PA: 7 MOZ Rank: 88
-
Jiangsu Hengrui - Wikipedia
https://en.wikipedia.org/wiki/Jiangsu_Hengrui
Jiangsu Hengrui Pharmaceuticals Company Ltd. (Chinese: 江苏恒瑞医药股份有限公司), also known as Jiangsu Hengrui (Chinese: 恒瑞医药), is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics ...
DA: 68 PA: 57 MOZ Rank: 64
-
Hengrui, Elevar strike $600M marketing deal for liver cancer med
https://www.fiercepharma.com/pharma/elevar-ponies-600m-take-hengruis-investigational-liver-cancer-cocktail-market-us-and-beyond
Oct 17, 2023 · Under the deal, Elevar is set to pay China’s Hengrui up to $600 million in milestones—plus potential royalties—to market the VEGFR rivoceranib combined with the PD-1 inhibitor camrelizumab ...
DA: 53 PA: 83 MOZ Rank: 94
-
Hengrui Oncology Collaboration | Merck
https://www.merckgroup.com/en/news/hengrui-oncology-collab-30-10-2023.html
Oct 30, 2023 · Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate. Merck today announced a strategic collaboration with Jiangsu Hengrui …
DA: 45 PA: 24 MOZ Rank: 99
-
Hengrui Pharma Partners with Merck KGaA, Darmstadt, …
https://www.prnewswire.com/news-releases/hengrui-pharma-partners-with-merck-kgaa-darmstadt-germany-to-advance-innovative-cancer-therapies-301970919.html
LIANYUNGANG, China, Oct. 30, 2023 /PRNewswire/ -- Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui Pharma"), a global pharmaceutical company focused on scientific and technological...
DA: 80 PA: 38 MOZ Rank: 42
-
China's Hengrui launches Luzsana with Big Pharma veterans
https://www.fiercepharma.com/pharma/startup-no-other-chinas-hengrui-launches-luzsana-big-pharma-veterans-top-and-goal-improve
May 18, 2022 · Originally Hengrui’s U.S. and European operations, Luzsana officially hangs its plaque Wednesday with a pipeline of 11 drugs from the parent led by China-approved PD-1 cancer immunotherapy...
DA: 43 PA: 85 MOZ Rank: 11
-
Jiangsu Hengrui Pharma and Elevar Therapeutics Announce
https://www.globenewswire.com/news-release/2023/10/17/2761595/0/en/Jiangsu-Hengrui-Pharma-and-Elevar-Therapeutics-Announce-Global-Commercialization-Licensing-Agreement-for-PD-1-Inhibitor-Camrelizumab-in-Combination-with-Rivoceranib-for-uHCC.html
Oct 17, 2023 · PRINCETON, N.J. and FORT LEE, N.J. Oct. 17, 2023 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), one of China’s largest pharmaceutical companies based on market...
DA: 100 PA: 7 MOZ Rank: 12
-
China's Hengrui eyes FDA filing for PD-1 liver cancer drug
https://www.fiercepharma.com/pharma/another-chinese-pd-1-immunotherapy-eyes-fda-application-hengrui-touts-win-liver-cancer
May 12, 2022 · Hengrui represents the latest example of a Chinese drugmaker trying to bring a PD-1/L1 inhibitor to the U.S. market. The first attempt by a Chinese firm, Innovent Biologics, and its partner, Eli...
DA: 39 PA: 39 MOZ Rank: 87
-
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) …
https://www.prnewswire.com/news-releases/jiangsu-hengrui-pharmaceuticals-co-ltd-hengrui-pharma-launches-luzsana-biotechnology-luzsana-301549670.html
PRINCETON, N.J., May 18, 2022 /PRNewswire/ -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) today announced that it is launching Luzsana Biotechnology™ (Luzsana), a global,...
DA: 35 PA: 1 MOZ Rank: 19
-
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
https://www.hrssd.com.cn/en/pipeline.html
Jiangsu Hengrui Pharmaceuticals Co., Ltd. SHR-1210 (camrelizumab) Anti-PD-1 Antibody. III. NDA. Launched. China. Global. SHR1258 (pyrotinib) EGFR/HER2/HER4 TKI. III. NDA. Launched. China. Global. SHR3162 (fuzuloparib) PARP Inhibitor. III. NDA. Launched. China. Global. SHR-1316. Anti-PD-L1 Antibody. III. NDA. Launched. China. Global. SHR3680.
DA: 6 PA: 63 MOZ Rank: 71